-
Something wrong with this record ?
The influence of treatment with somatostatin analogues on morphology, proliferative and apoptotic activity in GH-secreting pituitary adenomas
J. Čáp, J. Cerman, S. Němeček, M. Mareková, V. Hána, Z. Fryšák
Language English Country Great Britain
Document type Research Support, Non-U.S. Gov't
Grant support
NB6172
MZ0
CEP Register
- MeSH
- Adenoma drug therapy surgery pathology radiography secretion MeSH
- Apoptosis MeSH
- Cell Division MeSH
- Adult MeSH
- Fibrosis MeSH
- Immunohistochemistry MeSH
- Combined Modality Therapy MeSH
- Middle Aged MeSH
- Humans MeSH
- Human Growth Hormone secretion MeSH
- Pituitary Neoplasms drug therapy pathology surgery radiography secretion MeSH
- Aged MeSH
- Somatostatin analogs & derivatives therapeutic use MeSH
- Treatment Outcome MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Research Support, Non-U.S. Gov't MeSH
With the aim to investigate histopathological changes and proliferative and apoptotic activity in GH-secreting adenomas we compared 14 cases pre-treated with somatostatin analogues before surgery with a reference group of 17 un-pretreated ones. Besides routine histology, immunocytochemical detection of all pituitary hormones, caspase-3, cytokeratin-18, and "M30 antigen", its apoptosis-specific fragment was performed. Proliferation activity of the tumour was determined by the Ki-67 antigen expression. In treated adenomas more prominent regressive changes were found accompanied by compensatory increase in perivascular fibrosis. The Ki-67 labelling index was lower in treated group (mean 2.5, median 1.6 per mille) than in untreated patients (mean 9.4, median 5.0 per mille). The difference was statistically significant (p=0.049 using Mann-Whitney Rank Sum Test). Apoptosis was detected in only 2 of the 14 pre-treated adenomas, and it was more frequent (9/17) and more prominent in the untreated group.
References provided by Crossref.org
- 000
- 03046naa 2200565 a 4500
- 001
- bmc11023071
- 003
- CZ-PrNML
- 005
- 20130326082016.0
- 008
- 110801s2003 xxk e Eng||
- 009
- AR
- 024 __
- $a 10.1016/s0967-5868(03)00072-9 $2 doi
- 035 __
- $a (PubMed)12852883
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Čáp, Jan, $d 1953- $7 mzk2003190513
- 245 14
- $a The influence of treatment with somatostatin analogues on morphology, proliferative and apoptotic activity in GH-secreting pituitary adenomas / $c J. Čáp, J. Cerman, S. Němeček, M. Mareková, V. Hána, Z. Fryšák
- 314 __
- $a Second Department of Internal Medicine, Charles University, Hradec Kralove, Czech Republic. capj@lfhk.cuni.cz
- 520 9_
- $a With the aim to investigate histopathological changes and proliferative and apoptotic activity in GH-secreting adenomas we compared 14 cases pre-treated with somatostatin analogues before surgery with a reference group of 17 un-pretreated ones. Besides routine histology, immunocytochemical detection of all pituitary hormones, caspase-3, cytokeratin-18, and "M30 antigen", its apoptosis-specific fragment was performed. Proliferation activity of the tumour was determined by the Ki-67 antigen expression. In treated adenomas more prominent regressive changes were found accompanied by compensatory increase in perivascular fibrosis. The Ki-67 labelling index was lower in treated group (mean 2.5, median 1.6 per mille) than in untreated patients (mean 9.4, median 5.0 per mille). The difference was statistically significant (p=0.049 using Mann-Whitney Rank Sum Test). Apoptosis was detected in only 2 of the 14 pre-treated adenomas, and it was more frequent (9/17) and more prominent in the untreated group.
- 590 __
- $a bohemika - dle Pubmed
- 650 _2
- $a adenom $x farmakoterapie $x chirurgie $x patologie $x radiografie $x sekrece $7 D000236
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a apoptóza $7 D017209
- 650 _2
- $a buněčné dělení $7 D002455
- 650 _2
- $a kombinovaná terapie $7 D003131
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a fibróza $7 D005355
- 650 _2
- $a lidský růstový hormon $x sekrece $7 D019382
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a imunohistochemie $7 D007150
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a nádory hypofýzy $x farmakoterapie $x patologie $7 D010911
- 650 _2
- $a nádory hypofýzy $x chirurgie $x radiografie $x sekrece $7 D010911
- 650 _2
- $a somatostatin $x analogy a deriváty $x terapeutické užití $7 D013004
- 650 _2
- $a výsledek terapie $7 D016896
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Cerman, Jaroslav, $d 1942- $7 jn20000400365
- 700 1_
- $a Němeček, Stanislav, $d 1931-2016 $7 jk01083144
- 700 1_
- $a Řezáčová, Martina, $d 1972- $7 nlk20020124956
- 700 1_
- $a Hána, Václav, $d 1956- $7 xx0018430
- 700 1_
- $a Fryšák, Zdeněk $7 xx0082612
- 773 0_
- $t Journal of Clinical Neuroscience $w MED00166944 $g Roč. 10, č. 4 (2003), s. 444-448
- 910 __
- $a ABA008 $b x $y 2
- 990 __
- $a 20110802112237 $b ABA008
- 991 __
- $a 20130326082238 $b ABA008
- 999 __
- $a ok $b bmc $g 881912 $s 733001
- BAS __
- $a 3
- BMC __
- $a 2003 $x MED00166944 $b 10 $c 4 $d 444-448 $m Journal of clinical neuroscience $n J. clin. neurosci.
- GRA __
- $a NB6172 $p MZ0
- LZP __
- $a 2011-4B09/jvme
